ReviewFuture microbiology2013
Progress towards the prevention and treatment of norovirus infections.
Review in Future microbiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- The epidemiology of Norovirus in the Middle East and North Africa (MENA) region: a systematic review.Virology journal · 2017Pooled it
- Targeting norovirus RdRp: A computational study on the inhibitory potential of ursolic acid and apigenin-7-O-glucoside.Journal of Taibah University Medical Sciences · 2025Article
- Review
- Disulfide stabilization of human norovirus GI.1 virus-like particles focuses immune response toward blockade epitopes.NPJ vaccines · 2020Article
- Polyprotein processing and intermolecular interactions within the viral replication complex spatially and temporally control norovirus protease activity.The Journal of biological chemistry · 2019Article
- Human Norovirus NS3 Has RNA Helicase and Chaperoning Activities.Journal of virology · 2018Article
- Chronic norovirus infection and common variable immunodeficiency.Clinical and experimental immunology · 2017Review
- Norovirus drug candidates that inhibit viral capsid attachment to human histo-blood group antigens.Antiviral research · 2016Review
- Current tools for norovirus drug discovery.Expert opinion on drug discovery · 2016Review
- Advances Toward a Norovirus Antiviral: From Classical Inhibitors to Lethal Mutagenesis.The Journal of infectious diseases · 2016Article
- Anti-norovirus therapeutics: a patent review (2010-2015).Expert opinion on therapeutic patents · 2016Review
- Viruses in Rodent Colonies: Lessons Learned from Murine Noroviruses.Annual review of virology · 2015Review
- Norovirus immunology: Of mice and mechanisms.European journal of immunology · 2015Review
- Molecular chaperone Hsp90 is a therapeutic target for noroviruses.Journal of virology · 2015Article
- Structure-guided design and optimization of dipeptidyl inhibitors of norovirus 3CL protease. Structure-activity relationships and biochemical, X-ray crystallographic, cell-based, and in vivo studies.Journal of medicinal chemistry · 2015Article
- Burden of norovirus in healthcare facilities and strategies for outbreak control.The Journal of hospital infection · 2015Review
- Norovirus in healthcare settings.Current opinion in infectious diseases · 2014Review
- Advances in norovirus biology.Cell host & microbe · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Noroviruses are now recognized as the major cause of acute gastroenteritis in the developed world, yet our ability to prevent and control infection is limited. Recent work has highlighted that, while typically an acute infection in the population, immunocompromised patients often experience long-term infections that may last many years. This cohort of patients and those regularly exposed to infectious material, for example, care workers and others, would benefit greatly from the development of a vaccine or antiviral therapy. While a licensed vaccine or antiviral has yet to be developed, work over the past 10 years in this area has intensified and trials with a vaccine candidate have proven promising. Numerous antiviral targets and small molecule inhibitors that have efficacy in cell culture have now been identified; however, further studies in this area are required in order to make these suitable for clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.